Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.

Parry R, Schneider D, Hudson D, Parkes D, Xuan JA, Newton A, Toy P, Lin R, Harkins R, Alicke B, Biroc S, Kretschmer PJ, Halks-Miller M, Klocker H, Zhu Y, Larsen B, Cobb RR, Bringmann P, Roth G, Lewis JS, Dinter H, Parry G.

Cancer Res. 2005 Sep 15;65(18):8397-405.

2.

111In-CHX-A''-DTPA-anti-mindin/RG-1 monoclonal antibody 19G9.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2009 Nov 16 [updated 2009 Dec 03].

3.

Radioimmunotherapy of prostate cancer.

Smith-Jones PM.

Q J Nucl Med Mol Imaging. 2004 Dec;48(4):297-304. Review.

4.

New antibody conjugates in cancer therapy.

Govindan SV, Goldenberg DM.

ScientificWorldJournal. 2010 Oct 12;10:2070-89. doi: 10.1100/tsw.2010.191. Review.

5.

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.

Clin Genitourin Cancer. 2006 Mar;4(4):249-56. Review.

PMID:
16729907
6.

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI.

Curr Oncol Rep. 2004 May;6(3):222-9. Review.

PMID:
15066234
7.

Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer.

Morris MJ, Pandit-Taskar N, Divgi C, Larson S, Scher HI.

Curr Urol Rep. 2005 May;6(3):163-70. Review.

PMID:
15869719
8.

Radioimmunoscintigraphy of prostate cancer.

Babaian RJ, Lamki LM.

Semin Nucl Med. 1989 Oct;19(4):309-21. Review.

PMID:
2678482
9.

Targeted alpha-therapy for control of micrometastatic prostate cancer.

Li Y, Russell PJ, Allen BJ.

Expert Rev Anticancer Ther. 2004 Jun;4(3):459-68. Review.

PMID:
15161444
10.

Diagnostic and therapeutic utility of monoclonal antibodies in urologic oncology.

McCarley DL, Weiner RS.

Semin Surg Oncol. 1989;5(4):293-301. Review.

PMID:
2672236
11.

86Y-CHX-A''-Diethylenetriamine pentaacetic acid-bevacizumab.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Dec 17 [updated 2011 Mar 16].

12.

Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90.

Hnatowich DJ, Snook D, Rowlinson G, Stewart S, Epenetos AA.

Targeted Diagn Ther. 1988;1:353-74. Review. No abstract available.

PMID:
2979062
13.

Current status of monoclonal antibodies for imaging and therapy of prostate cancer.

Bander NH.

Semin Oncol. 1994 Oct;21(5):607-12. Review.

PMID:
7939751
14.

The neuronal class 2 TSR proteins F-spondin and Mindin: a small family with divergent biological activities.

Feinstein Y, Klar A.

Int J Biochem Cell Biol. 2004 Jun;36(6):975-80. Review.

PMID:
15094111
15.

'Image and treat': an individualized approach to urological tumors.

Bouchelouche K, Capala J.

Curr Opin Oncol. 2010 May;22(3):274-80. doi: 10.1097/CCO.0b013e3283373d5c. Review.

Items per page

Supplemental Content

Write to the Help Desk